Bolt Biotherapeutics (BOLT) Other Non-Current Liabilities (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Other Non-Current Liabilities of $158000.0 for Q1 2026, up 19.7% sequentially from $132000.0 in Q4 2025, and up 19.7% YoY from $132000.0 in Q1 2025.
Bolt Biotherapeutics (BOLT) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $158000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 19.7% year-over-year to $158000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $158000.0 (up 19.7% YoY) and the FY2025 annual result came in at $132000.0, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $158000.0 in Q1 2026 per BOLT's latest filing, from $132000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $204000.0 in Q1 2022 and troughed at $42000.0 in Q4 2022.
- A 4-year average of $115846.2 and a median of $132000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities sank 80.0% in 2022, then advanced 19.7% in 2026.
- Over 4 years, Other Non-Current Liabilities stood at $42000.0 in 2022, then advanced by 2.38% to $43000.0 in 2023, then soared by 206.98% to $132000.0 in 2025, then gained by 19.7% to $158000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $158000.0, $132000.0, and $133000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 133,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 43,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 200,000.00 |
| Mar 31, 2022 | 204,000.00 |
| Dec 31, 2021 | 210,000.00 |
| Sep 30, 2021 | 217,000.00 |
| Jun 30, 2021 | 233,000.00 |
| Mar 31, 2021 | 321,000.00 |
| Dec 31, 2020 | 329,000.00 |